Back to top

Image: Bigstock

IDEXX Laboratories, Inc.

Read MoreHide Full Article

IDEXX exited the fourth quarter on a solid note. The company continues to demonstrate solid growth globally on consistent consumable revenue gains. Management’s innovation-based global strategy is leading to CAG Diagnostics growth. Notably, IDEXX recently commercially launched Catalyst SDMA Test in North America. Solid organic revenue growth along with a raised guidance for 2018 buoys optimism. Moreover, over the past year, IDEXX has been trading above the broader industry. However, its high dependence on third-party distributors and intense competition continue to pose threats. The stock’s overvaluation is also a concern.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

IDEXX Laboratories, Inc. (IDXX) - free report >>

Published in